NovaBay Pharmaceuticals Announces Strategic Shift in U.S. Avenova Commercialization Strategy

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova® for the domestic eye care market, announces a strategic shift in its U.S. commercialization strategy to support growth in Avenova sales and maintain cost effectiveness, along with changes to its Board of Directors and executive management team. NovaBay announces a strategic shift to deploy its sales representatives only in high-p

Full Story →